PMID- 27899970
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20200930
IS  - 1792-1074 (Print)
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Linking)
VI  - 12
IP  - 5
DP  - 2016 Nov
TI  - FISH testing of HER2 immunohistochemistry 1+ invasive breast cancer with 
      unfavorable characteristics.
PG  - 3115-3122
AB  - Diagnostic assays for human epidermal growth factor receptor 2 (HER2) expression 
      have a high predictive value because patients with HER2-positive tumors could 
      benefit from HER2-targeted therapy. The aim of the present study is to analyze 
      the incidence of HER2 gene amplification in selected tumors with adverse features 
      that scored 1+ by immunohistochemistry (IHC). For that purpose, 331 consecutive 
      invasive breast cancers (IBCs) were tested by IHC for HER2 expression between 
      January and December 2013, 102 of which (31%) scored 1+. Of these 102 women with 
      IBC who underwent surgery, 75 entered the study (73.5%). A total of 48 out of 75 
      (64%) IBC samples (patients' median age, 60.75 years) were selected according to 
      >/=1 unfavorable tumor characteristics, and tested by fluorescence in situ 
      hybridization (FISH). Of these 48 IBC samples scoring 1+ by IHC, 22 (46%) 
      exhibited high histological grade (G3), 23 (48%) had a high proliferative index 
      (Ki-67, >30%), 27 (56%) showed vascular invasion and 32 out of 41 evaluable cases 
      (78%) were node-positive. Regarding hormone receptor expression, 3 (6%) and 10 
      (21%) cases were negative for estrogen and progesterone receptors expression, 
      respectively. FISH was performed on 48 IBC cases scoring 1+ by IHC, and 7 
      infiltrating ductal carcinomas (IDCs) (14.6%) demonstrated HER2 amplification 
      with a high proliferative index. In 42 IDC samples, statistical analysis 
      evidenced a significant association between histological grade and high 
      proliferative index (P=0.0200). In addition, in 48 HER2 scoring 1+ IBCs, Fisher's 
      exact test evidenced a significant association between the presence of gene 
      amplification and high proliferative index (P=0.0033). Based on these 
      biopathological parameters, particularly a high proliferative index, the present 
      results indicate that it is possible to of identify tumors scoring 1+ by IHC with 
      HER2 amplification by FISH, thus aiding the selection of patients who are 
      suitable for HER2-targeted therapy according to an acceptable cost/benefit ratio.
FAU - Petroni, Stella
AU  - Petroni S
AD  - Department of Pathology, National Cancer Research Institute 'Giovanni Paolo II', 
      Bari I-70124, Italy.
FAU - Caldarola, Lucia
AU  - Caldarola L
AD  - Department of Pathology, National Cancer Research Institute 'Giovanni Paolo II', 
      Bari I-70124, Italy.
FAU - Scamarcio, Rachele
AU  - Scamarcio R
AD  - Department of Emergency and Organ Transplants, University of Bari Aldo Moro, Bari 
      I-70124, Italy.
FAU - Giotta, Francesco
AU  - Giotta F
AD  - Medical Oncology Unit, National Cancer Research Centre Institute 'Giovanni Paolo 
      II', Bari I-70124, Italy.
FAU - Latorre, Agnese
AU  - Latorre A
AD  - Medical Oncology Unit, National Cancer Research Centre Institute 'Giovanni Paolo 
      II', Bari I-70124, Italy.
FAU - Mangia, Anita
AU  - Mangia A
AD  - Functional Biomorphology Laboratory, National Cancer Research Centre Institute 
      'Giovanni Paolo II', Bari I-70124, Italy.
FAU - Simone, Giovanni
AU  - Simone G
AD  - Department of Pathology, National Cancer Research Institute 'Giovanni Paolo II', 
      Bari I-70124, Italy.
LA  - eng
PT  - Journal Article
DEP - 20160913
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC5103906
OTO - NOTNLM
OT  - HER2
OT  - fluorescence in situ hybridization
OT  - immunohistochemistry score 1+
OT  - invasive breast cancer
OT  - targeted therapies
EDAT- 2016/12/03 06:00
MHDA- 2016/12/03 06:01
PMCR- 2016/09/13
CRDT- 2016/12/01 06:00
PHST- 2015/10/12 00:00 [received]
PHST- 2016/05/19 00:00 [accepted]
PHST- 2016/12/01 06:00 [entrez]
PHST- 2016/12/03 06:00 [pubmed]
PHST- 2016/12/03 06:01 [medline]
PHST- 2016/09/13 00:00 [pmc-release]
AID - OL-0-0-5125 [pii]
AID - 10.3892/ol.2016.5125 [doi]
PST - ppublish
SO  - Oncol Lett. 2016 Nov;12(5):3115-3122. doi: 10.3892/ol.2016.5125. Epub 2016 Sep 
      13.